AI Article Synopsis

  • The study focused on the rates of stillbirth and neonatal mortality in pregnancies with congenital heart disease (CHD) and chromosomal trisomies (13, 18, and 21) from 2000-2020.
  • A total of 160 patients were evaluated, with 61.3% of families choosing to terminate the pregnancy; of those who continued, 25.8% experienced fetal death during pregnancy or delivery.
  • Live birth rates varied significantly by trisomy: 47.6% for trisomy 13/18 and 87.8% for trisomy 21, with a substantial portion of trisomy 21 infants surviving their first year.

Article Abstract

Fetal congenital heart disease (CHD) is often associated with chromosomal abnormalities. Our primary aim was to assess stillbirth and neonatal mortality rates for pregnancies complicated by trisomies 13, 18, and 21 in the presence of CHD, from a single tertiary referral center during 2000-2020 in a retrospective cohort study. The secondary aims were to investigate maternal morbidity in these pregnancies, and to study the gestational or neonatal age when mortality occurred. Inclusion criteria were the prenatal diagnosis of at least one structural CHD, together with prenatally diagnosed fetal trisomy 13, 18, or 21. One-hundred and sixty patients with fetal trisomy 13 (14.4%), fetal trisomy 18 (28.8%), and fetal trisomy 21 (56.9%) were evaluated. In total, 98 (61.3%) families opted for the termination of pregnancy (TOP). Of the remaining 62 (38.8%) pregnancies, 16 (25.8%) resulted in intrauterine fetal death/death during delivery. Ten out of twenty-one (47.6%) infants with trisomy 13 or 18 were born alive. The livebirth rate was 87.8% (36/41) for infants with trisomy 21. Early neonatal death was observed in nine (19.6%) infants. Thirty-one (86.1%) infants with trisomy 21 survived the first year of life. These data may be helpful for counseling affected parents when the decision to terminate or continue the pregnancy should be considered.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9410270PMC
http://dx.doi.org/10.3390/life12081223DOI Listing

Publication Analysis

Top Keywords

fetal trisomy
16
infants trisomy
12
prenatal diagnosis
8
trisomy
8
congenital heart
8
heart disease
8
fetal
6
outcome prenatal
4
diagnosis trisomy
4
trisomy fetuses
4

Similar Publications

Best Practice & Research clinical obstetrics & gynaecology.

Best Pract Res Clin Obstet Gynaecol

December 2024

University of California, San Francisco, Department of Obstetrics, Gynecology, and Reproductive Sciences, Division of Maternal-Fetal Medicine, 1825 Fourth St, Third Floor, San Francisco, CA, 94158, USA; University of California, San Francisco, Institute of Human Genetics, 1825 Fourth St, Third Floor, San Francisco, CA, 94158, USA. Electronic address:

Screening for fetal genetic disorders is a focus of prenatal care. Cell free DNA (cfDNA) screening for aneuploidies became available in 2011. Initially available only to high-risk individuals, this test is now standard of care in many settings.

View Article and Find Full Text PDF

The advent of non-invasive prenatal testing (NIPT) in the screening of fetal abnormalities has optimized prenatal care and decreased the rate of invasive diagnostic tests. In this retrospective descriptive study, we began with 1874 singleton pregnancies. After exclusion of some cases, the study cohort ended up with 1674 cases.

View Article and Find Full Text PDF

Role of copy number variation analysis in prenatally diagnosed Blake's pouch cyst.

BMC Pregnancy Childbirth

December 2024

Department of Ultrasound, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Maternal and Child Health Care Hospital, Beijing, 100026, China.

Background: Blake's pouch cyst (BPC) is a midline cystic anomaly of the posterior fossa. BPC has been shown to have a risk of aneuploidy prenatally. Copy number variation (CNV) and/or genetic syndromes have been reported in a few prenatal/postnatal cases with BPC.

View Article and Find Full Text PDF

T2DM detection methods are commonly used in teens and adults but are generally unsuitable to unborn fetuses in the context of non-invasive prenatal testing (NIPT). Biophysical and biochemical tests for fetuses are often invasive, carry risks, and have low sensitivity and specificity, with no direct method available to diagnose T2DM in utero. In contrast, cell-free DNA (cfDNA) is known have high sensitivity (93-98 %) and specificity (94-100 %) for cancer detection and fetal genetic disorders (trisomy 21, 8, and 13) making it applicable for fetal epigenetic and genetic analysis, including T2DM early detection.

View Article and Find Full Text PDF

Objectives: This study aimed to evaluate the association of aberrant right subclavian artery (ARSA) with genetic abnormalities and postnatal symptomatology, by comparing isolated and non-isolated ARSA cases.

Methods: Retrospective, descriptive and comparative study involving fetuses diagnosed with ARSA during routine fetal ultrasound scans, between 19 and 40 weeks, in a tertiary referral university hospital in Barcelona from January 2007 to December 2023.

Results: Out of 154 fetuses diagnosed with ARSA, 75.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!